Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department

Springer Science and Business Media LLC - 2022
Razban Mohammad1, Aristomenis K. Exadaktylos2, Vincent Della Santa3, Eric Heymann3
1Department of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland
2Department of Emergency Medicine, University Hospital of Bern, Bern, Switzerland
3Department of Emergency Medicine, Cantonal Hospital of Neuchatel, Neuchatel, Switzerland

Tóm tắt

Abstract Background Cannabis-related medical consultations are increasing worldwide, a non-negligible public health issue; patients presenting to acute care traditionally complain of abdominal pain and vomiting. Often recurrent, these frequent consultations add to the congestion of already chronically saturated emergency department(s) (ED). In order to curb this phenomenon, a specific approach for these patients is key, to enable appropriate treatment and long-term follow-up. Objectives This study reviews cannabinoid hyperemesis syndrome (CHS) and cannabis withdrawal syndrome (CWS), in a bid to help promote better understanding and handling of pathologies associated with chronic cannabis use. Following a literature review, we present a novel therapeutic algorithm aimed at guiding clinicians, in a bid to improve long-term outcomes and prevent recurrences. Methods Using the keywords “Cannabis,” “Hyperemesis,” “Syndrome,” “Withdrawal,” and “Emergency Medicine,” we completed a literature review of three different electronic databases (PubMed®, Google scholar®, and Cochrane®), up to November 2021. Results Although often presenting with similar symptoms such as abdominal pain and vomiting, cannabinoid hyperemesis syndrome (CHS) and cannabis withdrawal syndrome (CWS) are the result of two differing pathophysiological processes. Distinguishing between these two syndromes is essential to provide appropriate symptomatic options. Conclusion The correct identification of the underlying cannabis-related syndrome, and subsequent therapeutic choice, may help decrease ED presentations. Our study emphasizes the importance of both acute care and long-term outpatient follow-up, as key processes in cannabis-related disorder treatment.

Từ khóa


Tài liệu tham khảo

Baraniecki R, Panchal P, Malhotra DD, et al. Acute cannabis intoxication in the emergency department: the effect of legalization. BMC Emerg Med. 2021;21:32. https://doi.org/10.1186/s12873-021-00428-0.

OFSP - Office fédéral de la santé publique. Consommation de cannabis: faits et chiffres. https://www.bag.admin.ch/bag/fr/home/zahlen-und-statistiken/zahlen-fakten-zu-sucht/zahlen-fakten-cannabis.html. Accessed 05.2021.

Tramèr MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:6. https://doi.org/10.1136/bmj.323.7303.16.

Darmani NA. Cannabinoid-induced hyperemesis: a conundrum—from clinical recognition to basic science mechanisms. Pharmaceuticals. 2010;3(7):2163–77. https://doi.org/10.3390/ph3072163.

Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53(11):1566–70. https://doi.org/10.1136/gut.2003.036350.

Huestis, Marilyn A. Human Cannabinoid pharmacokinetics chemistry and biodiversity 4, no 8 2007; 1770-1804. DOI: https://doi.org/10.1002/cbdv.200790152

Russo EB, Spooner C, May L, Leslie R, Whiteley VL. Cannabinoid hyperemesis syndrome survey and genomic investigation. Cannabis Cannabinoid Res. 2022;7:336–44. https://doi.org/10.1089/can.2021.0046.

Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology. 2016;151(2):252–66. https://doi.org/10.1053/j.gastro.2016.04.015.

DeVuono MV, Parker LA. Cannabinoid hyperemesis syndrome: a review of potential mechanisms. Cannabis Cannabinoid Res. 2020;5:132–44. https://doi.org/10.1089/can.2019.0059.

DeVuono MV, Parker LA. Cannabinoid hyperemesis syndrome: a review of potential mechanisms. Cannabis Cannabinoid Res. 2020;5:132–44. https://doi.org/10.1089/can.2019.0059.

Lichtman A, Jl W, Kl LV, St N, Db A, Dm W, et al. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Eur J Pharmacol. 1998;357(2-3):139–48. https://doi.org/10.1016/s0014-2999(98)00558-5.

Amir E, James MS, Paul DM. Cannabis in the arm: what can we learn from intravenous cannabinoid studies? Curr Pharm Des. 2012;18(32):4906–14. https://doi.org/10.2174/138161212802884618.

Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9–37. https://doi.org/10.2147/sar.s109576.

Gorelick DA, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, et al. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend. 2012;123(1-3):141–7. https://doi.org/10.1016/j.drugalcdep.2011.11.007.

Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. J Med Toxicol. 2017;13(1):71–87. https://doi.org/10.1007/s13181-016-0595-z.

Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241–9. https://doi.org/10.2174/1874473711104040241.

Chu F, Cascella M. Cannabinoid hyperemesis syndrome. Treasure Island (FL): StatPearls 2021. https://www.ncbi.nlm.nih.gov/books/NBK549915. Accessed 05.2021.

Sun S, Zimmermann AE. Cannabinoid hyperemesis syndrome. Hosp Pharm. 2013;48(8):650–5. https://doi.org/10.1310/hpj4808-650.

Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87(2):114–9. https://doi.org/10.1016/j.mayocp.2011.10.005.

Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92. https://doi.org/10.1053/j.gastro.2016.02.011.

Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. DSM-5 cannabis withdrawal syndrome: demographic and clinical correlates in U.S. adults. Drug Alcohol Depend. 2019;195(170-7). https://doi.org/10.1016/j.drugalcdep.2018.09.005.

Katz G, Lobel T, Tetelbaum A, Raskin S. Cannabis withdrawal - a new diagnostic category in DSM-5. Isr J Psychiatry Relat Sci. 2014;51(4):270–5.

Richards JR, Gordon BK, Danielson AR, Moulin AK. Pharmacologic treatment of cannabinoid hyperemesis syndrome: a systematic review. Pharmacother J Hum Pharmacol Drug Ther. 2017;37(6):725–34. https://doi.org/10.1002/phar.1931.

Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, et al. Cannabinoid hyperemesis syndrome: public health implications and a novel model treatment guideline. West J Emerg Med. 2018;19(2):380–6. https://doi.org/10.5811/westjem.2017.11.36368.

Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Intravenous haloperidol versus ondansetron for cannabis hyperemesis syndrome (HaVOC): a randomized, controlled trial. Ann Emerg Med. 2021;77:613–9. https://doi.org/10.1016/j.annemergmed.2020.08.021.

Lee C, Greene SL, Wong A. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome. Clin Toxicol. 2019;57(9):773–7. https://doi.org/10.1080/15563650.2018.1564324.

Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database Syst Rev. 2015;9):CD010106. https://doi.org/10.1002/14651858.cd010106.pub2.

Pourmand A, Esmailian G, Mazer-Amirshahi M, Lee-Park O, Tran QK. Topical capsaicin for the treatment of cannabinoid hyperemesis syndrome, a systematic review and meta-analysis. Am J Emerg Med. 2021;43:35–40. https://doi.org/10.1016/j.ajem.2021.01.004.

McConachie SM, Caputo RA, Wilhelm SM, Kale-Pradhan PB. Efficacy of capsaicin for the treatment of cannabinoid hyperemesis syndrome: a systematic review. Ann Pharmacother. 2019;53(11):1145–52. https://doi.org/10.1177/1060028019852601.

Brezing CA, Levin FR. The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacol. 2018;43(1):173–94. https://doi.org/10.1038/npp.2017.212.

Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86(1):22–9. https://doi.org/10.1016/j.drugalcdep.2006.04.014.

Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacololgy. 2004;29(1):158–70. https://doi.org/10.1038/sj.npp.1300310.

Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116(1-3):142–50. https://doi.org/10.1016/j.drugalcdep.2010.12.010.

Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281–91. https://doi.org/10.1001/jamapsychiatry.2013.3947.

Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl). 2016; 233(13):2469-2478. DOI: https://doi.org/10.1007/s00213-016-4298-6

Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2012;37(7):1689–98. https://doi.org/10.1038/npp.2012.14.

Kelly JF, Yeterian JD, Cristello JV, Kaminer Y, Kahler CW, Timko C. Developing and testing twelve-step facilitation for adolescents with substance use disorder: manual development and preliminary outcomes. Subst Abuse Res Treat 2016;10:55-64. DOI: https://doi.org/10.4137/SART.S39635

Budney AJ, Vandrey RG, Stanger C. Pharmacological and psychosocial interventions for cannabis use disorders. Revista brasileira de psiquiatria. 2010;32 Suppl 1(01):S46–55.

Mj Z, Dj P, Garey L, Manning K, Jbd H, Buckner J, et al. Perceived barriers for cannabis cessation: relations to cannabis use problems, withdrawal symptoms, and self-efficacy for quitting. Addict Behav. 2018;76(45-51). https://doi.org/10.1016/j.addbeh.2017.07.011.

Irons JG, Babson KA, Bergeria CL, Bonn-Miller MO. Physical activity and cannabis cessation. Am J Addict. 2014;23(5):485–92. https://doi.org/10.1111/j.1521-0391.2014.12135.x.

Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug and alcohol dependence. 2011;117(1):38–44. https://doi.org/10.1016/j.drugalcdep.2011.01.003.

Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol. 2013;18:993–1002. https://doi.org/10.1111/j.1369-1600.2012.00461.x.

Bollom A, Austrie J, Hirsch W, Nee J, Friedlander D, Iturrino J, et al. Emergency Department burden of nausea and vomiting associated with cannabis use disorder: U.S. trends from 2006 to 2013. J Clin Gastroenterol. 2018;52(9):778–83. https://doi.org/10.1097/mcg.0000000000000944.

Chung T, Martin CS, Cornelius JR, Clark DB. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addict Abingdon Engl 2008; 103(5):787-799. DOI: 10.1111%2Fj.1360-0443.2008.02158.x

Ruger JP, Richter CJ, Spitznagel EL, Lewis LM. Analysis of costs, length of stay, and utilization of emergency department services by frequent users: implications for health policy. Acad Emerg Med Off J Soc Acad Emerg Med. 2004;11:1311–7. https://doi.org/10.1197/j.aem.2004.07.008.

OFSP - Office fédéral de la santé publique. Utilisation du cannabis à des fins médicales. https://www.bag.admin.ch/bag/fr/home/medizin-und-forschung/heilmittel/med-anwend-cannabis.html. 

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả